Waldenström's macroglobulinemia historical perspective: Difference between revisions
No edit summary |
Sara Mohsin (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Waldenström's macroglobulinemia}} | {{Waldenström's macroglobulinemia}} | ||
{{CMG}}{{AE}}{{RAK}} | {{CMG}}{{AE}} {{S.M.}} {{RAK}} | ||
==Overview== | ==Overview== | ||
Revision as of 15:33, 5 February 2019
|
Waldenström's macroglobulinemia Microchapters |
|
Differentiating Waldenström's macroglobulinemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Waldenström's macroglobulinemia historical perspective On the Web |
|
American Roentgen Ray Society Images of Waldenström's macroglobulinemia historical perspective |
|
FDA on Waldenström's macroglobulinemia historical perspective |
|
CDC on Waldenström's macroglobulinemia historical perspective |
|
Waldenström's macroglobulinemia historical perspective in the news |
|
Blogs on Waldenström's macroglobulinemia historical perspective |
|
Directions to Hospitals Treating Waldenström's macroglobulinemia |
|
Risk calculators and risk factors for Waldenström's macroglobulinemia historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2] Roukoz A. Karam, M.D.[3]
Overview
Waldenström macroglobulinemia was first discovered by Jan G. Waldenström, a Swedish physician in 1944.
Historical Perspective
Waldenström macroglobulinemia was first discovered by Jan G. Waldenström, a Swedish oncologist in 1944.[1]
References
- ↑ Waldenström, Jan (2009). "Incipient myelomatosis or «essential« hyperglobulinemia with fibrinogenopenia - a new syndrome?". Acta Medica Scandinavica. 117 (3–4): 216–247. doi:10.1111/j.0954-6820.1944.tb03955.x. ISSN 0001-6101.